- Home
- MBWM vs URGN Comparison
MBWM vs URGN Comparison
Compare MBWM & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBWM
- URGN
- Stock Information
- Founded
- MBWM 1997
- URGN 2004
- Country
- MBWM United States
- URGN United States
- Employees
- MBWM N/A
- URGN N/A
- Industry
- MBWM Major Banks
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- MBWM Finance
- URGN Health Care
- Exchange
- MBWM Nasdaq
- URGN Nasdaq
- Market Cap
- MBWM 740.5M
- URGN 830.4M
- IPO Year
- MBWM 1997
- URGN 2017
- Fundamental
- Price
- MBWM $43.82
- URGN $19.85
- Analyst Decision
- MBWM Buy
- URGN Strong Buy
- Analyst Count
- MBWM 4
- URGN 8
- Target Price
- MBWM $52.88
- URGN $28.50
- AVG Volume (30 Days)
- MBWM 67.7K
- URGN 929.7K
- Earning Date
- MBWM 10-21-2025
- URGN 11-06-2025
- Dividend Yield
- MBWM 3.51%
- URGN N/A
- EPS Growth
- MBWM 6.26
- URGN N/A
- EPS
- MBWM 5.27
- URGN N/A
- Revenue
- MBWM $233,714,000.00
- URGN $94,238,000.00
- Revenue This Year
- MBWM $10.34
- URGN $36.41
- Revenue Next Year
- MBWM $11.93
- URGN $118.04
- P/E Ratio
- MBWM $8.31
- URGN N/A
- Revenue Growth
- MBWM 5.19
- URGN 10.85
- 52 Week Low
- MBWM $37.76
- URGN $3.42
- 52 Week High
- MBWM $52.98
- URGN $21.71
- Technical
- Relative Strength Index (RSI)
- MBWM 42.75
- URGN 59.96
- Support Level
- MBWM $42.88
- URGN $16.95
- Resistance Level
- MBWM $45.58
- URGN $21.00
- Average True Range (ATR)
- MBWM 1.46
- URGN 1.04
- MACD
- MBWM -0.02
- URGN 0.36
- Stochastic Oscillator
- MBWM 28.38
- URGN 76.14
About MBWM Mercantile Bank Corporation
Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.